References
[1]. Baserga, R. (2005). “The Insulin-like Growth Factor-I
Receptor as a Target for Cancer Therapy”. Expert Opinion
on Therapeutic Targets, Vol. 9, No. 4, pp. 753-768.
[2]. Pollak, M. N., Schernhammer, E. S., and Hankinson, S.
E. (2004). “Insulin-like Growth Factors and Neoplasia”.
Nature Reviews Cancer, Vol. 4, No. 7, pp. 505-518.
[3]. Baserga, R., Peruzzi, F., and Reiss, K. (2003). “The IGF-1
Receptor in Cancer Biology”. International Journal of
Cancer, Vol. 107, No. 6, pp. 873-877.
[4]. Yu, H., and Rohan, T. (2000). “Role of the Insulin-like
Growth Factor Family in Cancer Development and
Progression”. Journal of the National Cancer Institute, Vol.
92, No. 18, pp. 1472-1489.
[5]. Baserga, R. (1995). “The Insulin-like Growth Factor I
Receptor: A Key to Tumor Growth?”. Cancer Research,
Vol. 55, No. 2, pp. 249-252.
[6]. Breuhahn, K., Nussbaum, T., Singer, S., and
Schirmacher, P. (2006). “The Insulin-Like Growth Factor
(IGF) Signaling Pathway: Strategies for Successful
Therapeutic Tasks in Cancer Treatment”. Current Cancer
Therapy Reviews, Vol. 2, No. 2, pp. 157-167.
[7]. He, G., Sung, Y. M., Di Giovanni, J., and Fischer, S. M.
(2006). “Thiazolidinediones Inhibit Insulin-Like Growth
Factor-I–Induced Activation of p70S6 Kinase and
Suppress Insulin-Like Growth Factor-I Tumor-Promoting
Activity”. Cancer Research, Vol. 66, No. 3, pp.1873-1878.
[8]. Garcia-Echeverria, C. (2006). “Medicinal Chemistry
Approaches to Target the Kinase activity of IGF-1R”.
IDrugs: the Investigational Drugs Journal, Vol. 9, No. 6, pp.
415-419.
[9]. Haluska, P., Carboni, J. M., Loegering, D. A., Lee, F. Y.,
Wittman, M., Saulnier, M. G., and Kaufmann, S. H. (2006).
“In vitro and in vivo antitumor effects of the dual insulin-like
growth factor-I/insulin receptor inhibitor, BMS-554417”. Cancer Research, Vol. 66, No. 1, pp. 362-371.
[10]. Wittman, M., Carboni, J., Attar, R., Bala
subramanian, B., Balimane, P., Brassil, P., and Eummer, J.
(2005). “Discovery of a 1 H-Benzoimidazol-2-yl)-1 Hpyridin-
2-one (BMS-536924) inhibitor of insulin-like growth
factor I receptor kinase with in vivo antitumor activity”.
Journal of Medicinal Chemistry, Vol. 48, No. 18, pp. 5639-
5643.
[11]. Carboni, J.M., Lee, A.V., Hadsell, D.L., Rowley, B.R.,
Lee, F.Y., Bol, D.K., and Hurlburt, W. (2005). “Tumor
development by transgenic expression of a constitutively
active insulin-like growth factor I receptor”. Cancer
Research, Vol. 65, No. 9, pp. 3781-3787.
[12]. Velaparthi, U., Liu, P., Balasubramanian, B., Carboni,
J., Attar, R., Gottardis, M., and Vyas, D. (2007). “Imidazole
moiety replacements in the 3-(1H-benzo [d] imidazol-2-yl)
pyridin-2 (1H)-one inhibitors of insulin-like growth factor
receptor-1 (IGF-1R) to improve cytochrome P450 profile”.
Bioorganic & Medicinal Chemistry Letters, Vol. 17, No. 11,
pp. 3072-3076.
[13]. Saulnier, M. G., Frennesson, D. B., Wittman, M. D.,
Zimmermann, K., Velaparthi, U., Langley, D. R., and
Greer, A. (2008). “2-(1H-Imidazol-4-yl) ethanamine and 2-
(1H-pyrazol-1-yl) ethanamine side chain variants of the
IGF-1R inhibitor BMS-536924”. Bioorganic & Medicinal
Chemistry Letters, Vol. 18, No. 5, pp. 1702-1707.
[14]. Zimmermann, K., Wittman, M. D., Saulnier, M. G.,
Velaparthi, U., Sang, X., Frennesson, D. B., and Li, A.
(2010). “SAR of PXR transactivation in benzimidazolebased
IGF-1R kinase inhibitors”. Bioorganic & Medicinal
Chemistry Letters, Vol. 20, No. 5, pp.1744-1748.
[15]. Velaparthi, U., Saulnier, M. G., Wittman, M. D., Liu, P.,
Frennesson, D. B., Zimmermann, K., and Clarke, W.
(2010). “Insulin-like growth factor-1 receptor (IGF-1R)
kinase inhibitors: SAR of a series of 3-[6-(4-substitutedpiperazin-
1-yl)-4-methyl-1H-benzimidazol-2-yl]-1Hpyridine-
2-one”. Bioorganic & Medicinal Chemistry Letters, Vol. 20, No. 10, pp. 3182-3185.
[16]. Wittman, M. D., Balasubramanian, B., Stoffan, K.,
Velaparthi, U., Liu, P., Krishnanathan, S., and Gottardis, M.
(2007). “Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one
inhibitors of insulin-like growth factor I (IGF-1R) kinase”.
Bioorganic & Medicinal Chemistry Letters, Vol.17, No. 4,
pp. 974-977.
[17]. Lipinski, C. A., Lombardo, F., Dominy, B. W., and
Feeney, P.J. (2012). “Experimental and computational
approaches to estimate solubility and permeability in
drug discovery and development settings”. Advanced
Drug Delivery Reviews, Vol. 64, pp. 4-17.
[18]. Afantitis, A., Melagraki, G., Sarimveis, H., Koutentis, P. A., Markopoulos, J., and Igglessi-Markopoulou, O. (2006). “A novel QSAR model for predicting induction of apoptosis by 4-aryl-4H-chromenes”. Bioorganic & Medicinal Chemistry, Vol. 14, No. 19, pp. 6686-6694.
[19]. Kim, D., Hong, S.I., and Lee, D.S. (2006). “The quantitative structure-mutagenicity relationship of polycylic aromatic hydrocarbon metabolites ”. International Journal of Molecular Sciences, Vol. 7, No. 12, pp. 556-570.
[20]. Jaworska, J., Nikolova-Jeliazkova, N., and Aldenberg, T. (2005). “QSAR applicability domain estimation by projection of the training set descriptor space: A review”. ATLA-NOTTINGHAM, Vol. 33, No. 5, pp. 445.
[21]. Afantitis, A., Melagraki, G., Sarimveis, H., Koutentis, P. A., Markopoulos, J., and Igglessi-Markopoulou, O. (2006). “Investigation of substituent effect of 1-(3, 3- diphenylpropyl)-piperidinylphenylacetamides on CCR5 binding affinity using QSAR and virtual screening techniques”. Journal of Computer-Aided Molecular Design, Vol. 20, No. 2, pp. 83-95.
[22]. Golbraikh, A., and Tropsha, A. (2002). “Beware of q 2!”. Journal of Molecular Graphics and Modelling, Vol. 20, No. 4, pp. 269-276.
[23].Hall, L.H., Mohney, B., and Kier, L.B. (1991). “The electrotopological state: structure information at the atomic level for molecular graphs”. Journal of Chemical Information and Computer Sciences, Vol. 31, No. 1, pp. 76-82.